Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer
ConclusionWhile well tolerated with a strong preclinical rationale, the combination of ruxolitinib and trastuzumab did not lead to an improvement in PFS compared to historical control in patients with trastuzumab-resistant metastatic HER2+ breast cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Hematology | HER2 | Herceptin | History of Medicine | Toxicology